-
Alnylam announces that Onpattro has been approved by MHLW for the treatment of amyloid degeneration partner polyneuropathy
Time of Update: 2020-06-09
recently, Alnylam company (http:// announced that its Onpattro (MHLW) has been approved by Japan's Ministry of Health, Labour and Welfare (MHLW) to treat hereditary-transthyroxinetic (hATTR) amyl
-
FDA approves Vyleesi for use in premenopausal women with libido
Time of Update: 2020-06-09
HSDD is one of the most common sexual dysfunctions among women, affecting about 6 million premenopausal women in the United States HSDD is characterized by decreased libido, accompanied by stress, w
-
Israel's Vaxival Bios develops cancer vaccine "ImMucin" to stop cancer recurrence
Time of Update: 2020-06-09
Recent lying news emerged that http:// an Israeli biotech company, had developed a revolutionary cancer vaccine, ImMucin, Vaxil Bios, specifically designed to prevent a recurrence after cancer tre
-
European Commission approves bluebird bio gene therapy ZYNTEGLO listing
Time of Update: 2020-06-09
blood transfusion-dependent beta-thalassemia is a serious genetic disease As a result of mutations in the genes that encode "beta globulin", hemoglobin levels in patients can decrease significantly
-
FDA approves Belimumab intravenous infusion for children under 5 years of age with systemic lupus
Time of Update: 2020-06-09
systemic lupus erythematosus (SLE), commonly referred to simply as lupus, is a serious chronic disease that causes inflammation and various body damage to tissues and organs Recently, the FDA (ht
-
NMPA approves U.S. pharmaceutical company Vimizim (elosulfase alfa) for treatment of MPS IVA
Time of Update: 2020-06-09
MPS IVA is caused by the inactivity of an enzyme involved in the metabolism of glycomine polysaccharides (GAG) The gradual accumulation of GAGs can cause severe lesions and multi-system clinical dam
-
Application for listing of new drug by Yousse Bisetozhu mono anti-drug approved by the State Drug Administration
Time of Update: 2020-06-09
Recently, The application for the listing of the new drug (http:// (JXSS1800003) submitted by Eussp ryto in China for the treatment of moderate to severe rheumatoid arthritis (RA) was approved by
-
FDA accepts new drug application for zejula, an oral PARP inhibitor, submitted by glaxoSmithKline
Time of Update: 2020-06-09
recently, GlaxoSmithKline (GSK) announced that the Us The FDA (http:// has accepted its submitted supplementtoly new drug (http:// application (http:// and will review it as a priority for PDU
-
FDA approves Mercay Weight PD-1 inhibitor favipiravir
Time of Update: 2020-06-09
today, the (http:// of the of MSD announced that the U.S the FDA's (http:// accelerate the approval of the company's heavy-duty PD-1 inhibitors According to a recent study, researchers at the
-
FDA approves Pfizer Vyndaqel and Vyndamax for treatment of myocardial disease caused by amyloid degeneration
Time of Update: 2020-06-09
AATR-CM is a rare, life-threatening disease It is caused by the instability of the TTR TTR usually exists in the form of tetrapolymers, which, when unstable tetrapolymers are dissofarted, cause setr
-
FibroGen announces interim results of Phase 2 clinical trial sparing DMD patients with the drug pamerevlumab
Time of Update: 2020-06-09
recently, FibroGen (http:// announced the interim results of the pamerevlumab, a drug (http:// for the treatment of Duchenne muscular dystrophy (DMD), in the of the Phase 2 clinical trial (
-
Nanjing Zhengda Tianqing 3 generic drug "Tegrelo" officially approved by the State Drug Administration (NMPA) for listing
Time of Update: 2020-06-09
yesterday (July 1), Nanjing Zhengda Tianqing 3 imitation Pharmaceutical (http:// "Tegrelo" was officially approved by the State Drug Administration (NMPA) for listing, becoming the third approved
-
NMPA quasi-anti-anti-anti-inflammatory drug Cimzia (Pesseli-pearl monoantigen) used to treat patients with rheumatoid arthritis
Time of Update: 2020-06-09
The National Pharmaceutical (http:// Regulatory Authority (NMPA) has approved the anti-inflammatory drug Cimzia (certolizumab pegol, pisserizumab single anti-injection) for treatment of patients
-
Anjin Angarvi ® (Tsu-mono-injection) approved by the State Drug Administration
Time of Update: 2020-06-09
osteoblastoma is a histologically benign, but often invasive bone tumor, which occurs in the young and middle age population between the ages of 20 and 40, and the incidence of female sons is slight
-
The forgreotablets (90mg) developed by Stone Pharmaceutical Group have been approved by the State Drug Administration for registration of drugs
Time of Update: 2020-06-09
recently, Stone Pharmaceutical Group announced that its affiliated company (http:// stone pharmaceutical group, O'Italian Pharmaceutical Co., Ltd developed for the Grelo tablets (90mg) has been i
-
Intec's innovative flu treatment Xofluza (baloxavir marboxil) reaches major end in Phase 3 clinical trial
Time of Update: 2020-06-09
Today, Roche's Genetech company, (http:// , announced that its innovative flu treatment, Baloxavir marboxil, had reached its main point in the global phase 3 clinical trial (http:// called MINI
-
NMPA approves New Anti-Cancer Drug Halaven for Use in Patients With LocalIzed Advanced or Metastatic Breast Cancer
Time of Update: 2020-06-09
today, The Regulatory Authority (NMPA) of China's Medicines (http:// has approved its in-house development of the new anti-cancer drug Halaven (eribulin mesylin, ereblin), for localized or metast
-
GSK new ICS/LABA drug Wanruishu ® officially enter the Chinese market
Time of Update: 2020-06-09
recently, GSK China announced that its new ICS/LABA Drug (http:// Wanruishu ® (generic name: fluoroteason/Verantro, FF/VI) has officially entered the Chinese market as the only once-a-day ICS/LA
-
FDA approves Praluent to reduce risk of heart attacks, strokes and heart pain requiring hospitalization
Time of Update: 2020-06-09
high levels of LDL-C in the blood, also known as "bad" cholesterol, can increase the risk of severe cardiovascular events in patients Adults who have had a heart attack or stroke are at a one-third
-
Lilly releases post-mortem data for the migraine drug Emgality Phase III clinical program
Time of Update: 2020-06-09
migraine is the second most disabled cause in the United States and can seriously affect the lives of patients Emgality treatment can effectively reduce the number of days of migraine attacks per mo
